Full video transcriptClick to expand
Auto-generated transcript of @tonyhuge.official's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Exactly how you're going to use Tessa Fencing, an SLUPP332 to lose 5 to 10% body fat in 5 weeks.
- 0:08This combo puts you in fat burning mode 24-7.
- 0:12First, Tessa Fencing, the 24-7 fat burner.
- 0:16Take 0.25 mg to 0.5 mg every morning on an empty stomach.
- 0:21It increases dopamine, serotonin, norepinephrine, so you feel full, focused, and dialed in all day.
- 0:28Cravings disappear, energy skyrockets, and your metabolism stays elevated even while you're resting.
- 0:35Second, SLUPP332, the metabolic accelerator.
- 0:39Take 20-30 mg daily with your first meal.
- 0:43It activates Rev ERB triggering cellular response that mimics the effects of exercise
- 0:49and ramps up fat oxidation.
- 0:51Even while you're doing nothing.
- 0:52No jitters, no crash, just real continuous fat burn.
- 0:56Together, Tessa Fencing controls the brain.
- 0:59SLUPP332 drives the body.
- 1:02You eat less, you burn more, and you lose 5-10% body fat in 5 weeks without the cardio grind or starvation.
- 1:10This is not a diet. This is engineered fat loss.
- 1:13If you want the full cheat sheet and the protocol that I use with my private clients,
- 1:16then comment Shred.
- 1:18You'll get the exact plan and will coach you through every step.
GLP-1 'stacks' for fat loss: what the evidence actually supports
Quick answer
Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human trial data showing meaningful weight loss but also cardiovascular side effects including elevated heart rate and blood pressure. SR9009 is a REV-ERB agonist with no completed human clinical trials and documented near-zero oral bioavailability in mammalian models, making its effects in humans speculative at best. Combining these two compounds without medical supervision presents unquantified pharmacological risk, and neither is approved by the FDA for any indication.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 'stacks' for fat loss: what the evidence actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 'stacks' for fat loss: what the evidence actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 'stacks' for fat loss: what the evidence actually supports" from Tony Huge. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human trial data showing meaningful weight loss but also cardiovascular side effects including elevated heart rate and blood pressure.
The reason this review is not generic is the source wording and the canonical claim label "glp1 this stack helped me drop 10 body fat without crash dieting." In this clip, the useful excerpt is: "Exactly how you're going to use Tessa Fencing, an SLUPP332 to lose 5 to 10% body fat in 5 weeks." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human trial data showing meaningful weight loss but also cardiovascular side effects including elevated heart rate and blood pressure.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human trial data showing meaningful weight loss but also cardiovascular side effects including elevated heart rate and blood pressure. SR9009 is a REV-ERB agonist with no completed human clinical trials and documented near-zero oral bioavailability in mammalian models, making its effects in humans speculative at best. Combining these two compounds without medical supervision presents unquantified pharmacological risk, and neither is approved by the FDA for any indication.
- Tesofensine has Phase 2 human trial data (Astrup et al., 2008, The Lancet) confirming appetite suppression and weight loss, but it also caused increased heart rate and blood pressure and was not approved for market.
- SR9009 has zero completed human clinical trials. Its effects described in the video are extrapolated from rodent studies and are not established in human physiology.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Tesofensine has Phase 2 human trial data (Astrup et al., 2008, The Lancet) confirming appetite suppression and weight loss, but it also caused increased heart rate and blood pressure and was not approved for market.
- SR9009 has zero completed human clinical trials. Its effects described in the video are extrapolated from rodent studies and are not established in human physiology.
- SR9009 has documented near-zero oral bioavailability in mammalian models, raising serious questions about whether oral dosing produces any meaningful systemic effect in humans at all.
- WADA prohibits SR9009 in competitive sport. Anyone subject to drug testing who uses this compound based on social media advice risks a violation.
- The 5-10% body fat in 5 weeks claim has no supporting human clinical data for either compound individually, let alone in combination.
- Neither tesofensine nor SR9009 is FDA-approved. Sourcing them outside a clinical setting means no regulatory oversight of purity, concentration, or safety.
- The video ends with a paid coaching upsell, a commercial conflict of interest that should factor into how viewers evaluate the confidence of every claim made before it.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @tonyhuge.official actually say?
Tony Huge claimed that combining tesofensine (which he called "Tessa Fencing") at 0.25-0.5 mg daily with SR9009 ("SLUPP332") at 20-30 mg daily will produce "5 to 10% body fat" loss in five weeks. He described tesofensine as a "24-7 fat burner" that "increases dopamine, serotonin, norepinephrine" and SR9009 as a "metabolic accelerator" that "mimics the effects of exercise." He positioned this as engineered fat loss requiring no cardio and no calorie restriction beyond reduced cravings.
The video ends with a lead-generation prompt asking viewers to comment "Shred" for a paid protocol. That commercial angle matters when evaluating the confidence of the claims being made.
Does the science back this up?
Tesofensine has real trial data behind it. SR9009 does not, at least not in humans. That asymmetry is the most important thing to understand about this stack.
Tesofensine is a triple monoamine reuptake inhibitor originally developed for Parkinson's disease. A randomized, double-blind Phase 2 trial by Astrup et al. (2008, The Lancet) found that 0.5 mg daily produced roughly 12.8 kg weight loss over 24 weeks in obese adults, significantly more than placebo. The appetite suppression mechanism Tony described, dopamine, serotonin, and norepinephrine reuptake inhibition, is pharmacologically accurate. So the basic science on tesofensine is not invented.
SR9009 is a different story entirely. It is a synthetic REV-ERB agonist studied in mice. Woldt et al. (2013, Nature Medicine) showed improved metabolic function in rodent models. But SR9009 has essentially zero oral bioavailability in mammals, a problem documented in the preclinical literature. No human clinical trials have been completed. Claiming it produces "real continuous fat burn" in humans is not supported by evidence.
What did they get wrong (or right)?
Tony got the tesofensine mechanism mostly right but made serious errors on SR9009 and on the timeline. Five weeks is not realistic for 5-10% body fat loss on any legal, non-surgical intervention, and presenting that figure as a standard outcome is misleading.
What he got right: tesofensine does inhibit reuptake of dopamine, serotonin, and norepinephrine. That is established pharmacology. Appetite suppression and modest metabolic rate increases have been documented in trials.
What he got wrong:
- SR9009's oral bioavailability problem makes his dosing protocol biologically questionable. Lipopolysaccharide-based delivery systems have been explored in animal research, but no human dosing standard exists. His "20-30 mg daily" figure comes from nowhere peer-reviewed.
- The claim that SR9009 "mimics the effects of exercise" is a dramatic overstatement of mouse data. Exercise produces systemic adaptations, including cardiac, musculoskeletal, and mitochondrial changes, that no single compound has replicated in humans.
- "5 to 10% body fat in 5 weeks" without a caloric deficit is not supported by any published human data on either compound, individually or combined.
- Neither substance is FDA-approved. Tesofensine remains investigational in the United States. SR9009 is a research chemical with no approved human use.
What should you actually know?
These are not supplements you can safely self-administer based on a TikTok protocol. One of them has no human safety data at all.
Tesofensine has shown real weight loss effects in trials, but it also carries cardiovascular risks. The Astrup 2008 Lancet trial documented increased heart rate and blood pressure. The compound was dropped from pharmaceutical development partly due to these concerns. Anyone with hypertension, cardiac history, or who takes other serotonergic or adrenergic drugs faces compounding risk.
SR9009 is frequently sold as a research chemical in gray markets. Because it bypasses any regulatory review, purity and dosing accuracy are unknown. The International Society of Sports Nutrition and WADA have both flagged REV-ERB agonists. WADA currently prohibits SR9009 in competition.
The five-week body composition claim also sets unrealistic expectations. Clinically meaningful fat loss in regulated GLP-1 trials like the SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, NEJM) took 72 weeks to reach roughly 20% body weight reduction. Credible fat loss takes time. Any protocol promising 5-10% in five weeks warrants serious skepticism regardless of what compounds are involved.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tony Huge · TikTok creator
31.6K views on this video
This Stack Helped Me Drop 10% Body Fat Without Crash Dieting Follow for more 🚨 THIS IS NOT MEDICAL OR LEGAL ADVICE! Don’t break the law. Don’t take risks with your health. Always consult a licensed medical professional before using any substances. #fatloss #fatburner #fatlosshelp #burnfat
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tesofensine has phase 2 human trial data (astrup et al.,?
Tesofensine has Phase 2 human trial data (Astrup et al., 2008, The Lancet) confirming appetite suppression and weight loss, but it also caused increased heart rate and blood pressure and was not approved for market.
What does the video say about sr9009 has zero completed human clinical trials. its effects described?
SR9009 has zero completed human clinical trials. Its effects described in the video are extrapolated from rodent studies and are not established in human physiology.
What does the video say about sr9009 has documented near-zero?
SR9009 has documented near-zero oral bioavailability in mammalian models, raising serious questions about whether oral dosing produces any meaningful systemic effect in humans at all.
What does the video say about wada prohibits sr9009 in competitive sport. anyone subject to drug?
WADA prohibits SR9009 in competitive sport. Anyone subject to drug testing who uses this compound based on social media advice risks a violation.
What does the video say about the 5-10% body fat in 5 weeks claim has no?
The 5-10% body fat in 5 weeks claim has no supporting human clinical data for either compound individually, let alone in combination.
What does the video say about neither tesofensine nor sr9009?
Neither tesofensine nor SR9009 is FDA-approved. Sourcing them outside a clinical setting means no regulatory oversight of purity, concentration, or safety.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tony Huge, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.